Tweets
#EULAR2026 POS0713 Is there a hope for BTK-inhibition in #SLE despite several previous failures? A Phase IIb RCT in China: primary endpoint (SRI-4) was met in Orelabrutinib vs PBO in dose-dependent manner. No new safety signal. Phase 3 RCT is underway @RheumNow https://t.co/4cJ8ezppTS
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 weeks 1 day ago
Gecacitinib (pan-JAK inhibitor) vs placebo in radiographic #axSpA ASAS40 51.9% vs 12.9% (p<0.0001) at 16 weeks. ASAS20 69.2% vs 21.2% (p<0.0001). Pan-JAK inhibition showed efficacy in TNFi-experienced patients. Abstr OP0240 @RheumNow #EULAR2026
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
2 weeks 2 days ago
#proof of #concept in #Sjogren’s #dis
#lanalumab Treatment reduced in #SjD
✅reduced B cells in #salivary #glands
—nearly complete depletion in serum
✅reduced B cell activation
✅improved #inflammation of
#parotid & #submandibular glands
@RheumNow #EULAR2026
#OP0163
#POS0284
Janet Pope @Janetbirdope ( View Tweet )
2 weeks 2 days ago
Interim results from ASTER, a study on real world effectiveness of ANI in SLE: Pts receiving ANI had improvements in total SLEDAI-2K scores after 1 yr ffup period
MCT, MSK & hema had the highest decrease in SLEDAI-2K scores from pre-tx to 1yr ffup
OP342 @RheumNow #EULAR2026 https://t.co/DArOwQtxM6
Links:
sheila @RHEUMarampa ( View Tweet )
2 weeks 2 days ago
ETA+MTX vs triple therapy after MTX failure in #RA: machine learning-emulated RACAT trial (n=3,472 VA pts) confirms ETA+MTX modestly better overall. But smoking matters: benefit disappears in current smokers. Precision medicine from RWD. @RheumNow #EULAR2026 POS0255
Jiha Lee @JihaRheum ( View Tweet )
2 weeks 2 days ago
Baricitinib inhibits substance P and IL6 - by interfering with the pathway NGF-IL6-SP axis. This is a novel pathway to pain suppression in RA
#EULAR2026 #pos0217 @rheumnow https://t.co/6MsrFH3Mm0
Bella Mehta @bella_mehta ( View Tweet )
2 weeks 2 days ago
#EULAR2026 POS0156 “TWO’S company, THREE’S a crowd” Tri-specific CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) TriTE via IV showed early efficacy & safety in 11 #SLE patients up to 48WKS. Longer FU needed to see if repeat dosing needed @RheumNow https://t.co/FpXzJIYwZF
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 weeks 2 days ago
Rapcabtagene Autoleucel -YTB323 rapidly manufactured CD19 CAR T
#POS0303 #EULAR2026 @RheumNow
24 months follow up data for 21 pts.
Durable b cell reduction and decrease in disease activity. https://t.co/m3lYjZJJIy
Links:
Bella Mehta @bella_mehta ( View Tweet )
2 weeks 2 days ago
#OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026 @RheumNow https://t.co/IJlDnHSTh2
Mrinalini Dey @DrMiniDey ( View Tweet )
2 weeks 2 days ago
Hypertension was the most robust and consistent predictor of pre term labor. Data from germany nationwide #POS1062 @RheumNow ##EULAR2026 https://t.co/Uccf11PpAK
Bella Mehta @bella_mehta ( View Tweet )
2 weeks 2 days ago
#OP0336 Exploratory analyses from REGENCY👑 OBI +standard tx induced ⬆️ histological remission & markedly greater kidney tissue B-cell depletion vs PBO in lupus nephritis. Many patients without clinical CRR still achieved histologic remission. #EULAR2026 @RheumNow #EULARBest https://t.co/DoOlRO9QsC
Mrinalini Dey @DrMiniDey ( View Tweet )
2 weeks 2 days ago
#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow
Mrinalini Dey @DrMiniDey ( View Tweet )
2 weeks 2 days ago
